IDEXX Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
IDEXX Laboratories has a total shareholder equity of $1.6B and total debt of $945.8M, which brings its debt-to-equity ratio to 60.3%. Its total assets and total liabilities are $3.4B and $1.8B respectively. IDEXX Laboratories's EBIT is $1.1B making its interest coverage ratio 41.8. It has cash and short-term investments of $397.4M.
Key information
60.3%
Debt to equity ratio
US$945.78m
Debt
Interest coverage ratio | 41.8x |
Cash | US$397.43m |
Equity | US$1.57b |
Total liabilities | US$1.78b |
Total assets | US$3.35b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IX1's short term assets ($1.5B) exceed its short term liabilities ($956.9M).
Long Term Liabilities: IX1's short term assets ($1.5B) exceed its long term liabilities ($827.7M).
Debt to Equity History and Analysis
Debt Level: IX1's net debt to equity ratio (35%) is considered satisfactory.
Reducing Debt: IX1's debt to equity ratio has reduced from 2017.2% to 60.3% over the past 5 years.
Debt Coverage: IX1's debt is well covered by operating cash flow (97.4%).
Interest Coverage: IX1's interest payments on its debt are well covered by EBIT (41.8x coverage).